Motor neuron degeneration in ALS involves mitochondrial damage, lipid peroxidation, and localized neuroinflammation. These interrelated cascades form a feed-forward cycle of cell injury.
┌──────────────────────────────────────┐
│ Mitochondrial Dysfunction │
└──────────────────┬───────────────────┘
│
Increased ROS Generation
│
▼
┌──────────────────────────────────────┐
│ Lipid Peroxidation (4-HNE Release) │
└──────────────────┬───────────────────┘
│
Inhibition of Glial Transporters
│
▼
┌──────────────────────────────────────┐
│ Elevated COX-2 & Inflammation │
└──────────────────────────────────────┘
Mitochondrial Pathology
Mitochondria in ALS motor neurons exhibit altered morphology and defective axonal transport. Primary drivers and consequences of mitochondrial failure include:
Causes: Accumulation of mutant proteins (e.g., mSOD1), impaired SERCA/RyR calcium handling, and electron transport chain (ETC) uncoupling.
Consequences: Depleted ATP generation, membrane depolarization, cytochrome C release, caspase activation, and apoptotic cell death.
Oxidative Stress and Lipid Peroxidation
Excessive reactive oxygen species (ROS) damage structural neurofilaments and cause lipid peroxidation. A key byproduct of lipid peroxidation is 4-Hydroxynonenal (4-HNE), which:
Binds directly to glial glutamate transporters, impairing clearance.
Impairs mitochondrial respiratory chain complexes.
Induces protein misfolding and disrupts axonal transport.
Microglial Activation and COX-2 Upregulation
Neuroinflammation in ALS is restricted to pathologically affected neural tissue. Comparative mRNA analyses demonstrate a selective 7-fold elevation of Cyclooxygenase-2 (COX-2) in affected ALS spinal cords compared to healthy controls or non-ALS neurodegenerative conditions (e.g., Alzheimer’s, Parkinson’s).
| Tissue Condition | COX-2 mRNA Level (Mean ± SEM) | COX-1 mRNA Level | CD11b (Microglial) Level |
| ALS Spinal Cord | 61.45 ± 13.92 (p < 0.0001) | 28.48 ± 1.10 | 17.03 ± 2.02 |
| Non-ALS Controls | 8.68 ± 1.11 | 25.03 ± 0.99 | 9.18 ± 0.92 |
| Alzheimer's Disease | 7.95 ± 1.46 | 23.91 ± 1.50 | 10.24 ± 1.28 |
| Parkinson's Disease | 7.98 ± 1.16 | 23.72 ± 1.39 | 10.85 ± 1.76 |
Key Takeaways
Mitochondrial energy failure and ROS generation trigger apoptotic pathways.
4-Hydroxynonenal (4-HNE) damages glial glutamate transporters and mitochondrial enzymes.
Selective COX-2 upregulation (>7-fold) highlights localized neuroinflammation in affected spinal segments.